Forcyte Biotechnologies
Commercializing the (UCLA-developed) FLECS Technology Platform for high-throughput analysis of contractile cell force.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $5.7m | Early VC | |
| Total Funding | 000k | ||
Related Content
Forcyte Biotechnologies is a biotechnology company that operates in the field of mechanobiology. The company has developed a proprietary technology platform, FLECS, for the discovery of small-molecule drugs. This platform is designed to visualize and quantify the mechanical forces, or "squeezing," of individual cells, which plays a role in various diseases.
The company's business model is centered around leveraging its FLECS platform to identify and develop new drug candidates. By mapping genomics and pharmacology to the mechanical functions of cells, Forcyte aims to discover drugs that can control these cellular forces. The primary clients for Forcyte's technology and drug discovery efforts are likely pharmaceutical and biotechnology companies interested in novel therapeutic approaches.
Forcyte Biotechnologies was founded in 2017 and is based in Los Angeles, California. The company has received seed funding and has a small team of employees. The market it operates in is the early-stage drug discovery and development sector, a high-risk, high-reward industry.
Keywords: mechanobiology, drug discovery, small-molecule drugs, cell mechanics, FLECS platform, genomics, pharmacology, biotechnology, therapeutic development, cellular forces